 |
 |
E-MOVE reports from the 61st Annual Meeting of the American Academy of Neurology, held in Seattle, WA, April 25th - May 2nd, 2009. Poster and Session numbers refer to their listing in Neurology, 2009;72(suppl3) Putaminal delivery of lentivirus containing dopamine synthesis genes is safe, according to a new study. Three PD patients ages 58-63 with disease duration of 8-16 years received bilateral injection to the putamen of ProSavin®, a viral vector carrying three genes: tyrosine hydroxylase, aromatic L-amino acid decarboxylase and GTP cyclohydrolase-1, which together convert tyrosine into dopamine. After 6 months, there was no worsening of dyskinesia, no antibodies detectable against the vector, and no vector genetic material detected in the periphery. Off- medication UPRDS-3 scores were 28% lower, and levodopa equivalents were 20% lower overall, with variable changes among the three patients individually. Further studies with higher doses in additional patients are ongoing. Prosavin® a lentiviral vector delivering the genes for dopamine biosynthesis is safe in patients with Parkinson's disease: Early report P Remy, JM Gurruchaga, G Fénelon, E Stratful, B Jarraya, H Lepetit, JP Lefaucheur, P Dolphin, I Gabriel, K Abhay, S Lavisse, A Kas, AL Ramelli, S Ralph, P Brugières, P Hantraye, SM Kingsman, KA Mitrophanous, S Palfi P01.012 ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn